Influenza Vaccine Safety and Effectiveness in Healthcare Providers

This study has suspended participant recruitment.
(Unable to measure vaccine effectivness in season following the Pandemic.)
Sponsor:
Collaborator:
PHAC/CIHR Influenza Research Network
Information provided by:
Dalhousie University
ClinicalTrials.gov Identifier:
NCT01282177
First received: January 7, 2011
Last updated: January 21, 2011
Last verified: January 2011
  Purpose

The overall objective of this study is to provide ongoing assessment of the safety and effectiveness of seasonal and pandemic H1N1 vaccines in the prevention of ILI (influenza like illness), ILI-associated work absenteeism, and laboratory-confirmed influenza in a cohort of Canadian HCP (Health care providers). Given the uncertainties around the timing of the provision of seasonal influenza immunization to HCP for the 2009/10 influenza season, this study will focus on evaluation of safety and effectiveness of pandemic influenza immunization in Year 1 and evaluation of all recommended influenza vaccines in Years 2 and 3.


Condition
Influenza

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Monitoring Seasonal and Pandemic Vaccine Safety and Effectiveness in Healthcare Providers:A Prospective Cohort Study

Resource links provided by NLM:


Further study details as provided by Dalhousie University:

Primary Outcome Measures:
  • Assessment of the safety and tolerability of seasonal and pandemic influenza vaccine among a cohort of HCP [ Time Frame: October to April each year ] [ Designated as safety issue: Yes ]
    Health care providers will receive automated email reminders with a link to report any changes in their health within 4 weeks of vaccination.


Secondary Outcome Measures:
  • To validate published ILI case definitions in a cohort of HCP [ Time Frame: October to April each year ] [ Designated as safety issue: No ]
    A cohort of HCP will be asked via an automated email to report the presence of an upper respiratory illness and to self collect a nasal swab to be tested for influenza.


Estimated Enrollment: 1600
Study Start Date: October 2009
Estimated Study Completion Date: June 2012
Estimated Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Detailed Description:

Participants in Year 1 (2009/10) will be recruited beginning Oct. 1 through the end of the pandemic H1N1 influenza immunization campaign.

Participants will be followed from the day of vaccination until the end of the influenza season approximately Oct-April for each season.

At the initial visit, participants will have 1 tube of blood (10cc) collected at the time of enrolment to determine baseline antibody titres against pandemic H1N1 and the influenza strains in the past and current year's seasonal influenza vaccines.

Participants will receive automated email reminders with links to follow-up web-based questionnaires at weekly intervals following the completion of the baseline survey and until the end of the influenza season.

If a participant reports a respiratory illness, they will receive a follow-up questionnaire asking details of the illness including the occurrence of respiratory illness and associated symptoms, contact with patients or household members that had respiratory illness, respiratory symptom-related healthcare utilization, prescription or over-the-counter products used for treatment of the respiratory illness, and number of days of work missed due to respiratory illness or worked with symptomatic respiratory tract infection. An email will be sent to each participant every Monday morning during the season reminding the participant to complete their weekly diary and report and send in their nasal swab if they have symptoms of an acute respiratory illness.

At the initial visit participants will be taught how to collect their nasal swab and will practice doing their own swab in the presence of the study nurse/research associate. Participants will be instructed to collect a nasal swab and return the swabs as soon as possible after onset of ILI or respiratory illness (target < 48h after onset). Participants will be asked to collect the swab if they develop symptoms compatible with a viral respiratory tract infection (fever without an apparent source OR new symptoms with at least 2 of the following -cough, runny/stuffy nose, sneezing, sore/scratchy throat, hoarseness, malaise, myalgia, headache, fatigue OR one local symptom (runny/stuffy nose, sneezing, sore/scratchy throat, hoarseness, cough) plus one systemic symptom (fever, malaise, myalgia, headache, fatigue). If they prefer, a nasopharyngeal swab will be collected by a member of the study team as soon as possible after the onset of symptoms.

  Eligibility

Ages Eligible for Study:   18 Years to 69 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

A cohort of adult HCP will be offered the opportunity to participate in this surveillance study at Influenza vaccination clinics in their health care facility

Criteria

Inclusion Criteria:

1)18-69 years old, inclusive, as of Sept. 1 on the year of enrolment; 2)understand the study, agree to its provisions, and give written informed consent to participate; 3)available for follow-up for at least 1 influenza season 4)have convenient access to a computer with internet access and basic skills for use of the internet; 5)employed full-or part -time (> 8 hours/week) in an acute care hospital (in any occupation) or, if a physician or midwife, working at least 8 hours per week in an acute care hospital.

Exclusion Criteria:

  1. planning to spend more than two consecutive weeks outside of Canada during the winter study period (Oct. 15- Apr. 15);
  2. received an immunoglobulin within 6 months of study entry;
  3. planning to take leave from work for more than two consecutive weeks during the winter study period (e.g. maternity or medical leave);
  4. participating in a trial that would result in receipt of an investigational medication during the study period
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01282177

Sponsors and Collaborators
Dalhousie University
PHAC/CIHR Influenza Research Network
Investigators
Principal Investigator: Shelly A McNeil, MD Dalhousie University
Principal Investigator: Allison McGeer, MD Mount Sinai Hospital, New York
Principal Investigator: Anne McCarthy, MD The Ottawa Hospital
Principal Investigator: Mark Loeb, MD Hamilton Health Sciences Center
Principal Investigator: Grant Stiver, MD Vancouver General Hospital
Principal Investigator: Brenda Coleman, MD Mount Sinai Hospital, New York
  More Information

No publications provided

Responsible Party: Dr Shelly McNeil -Principal Investigator, Dalhousie University
ClinicalTrials.gov Identifier: NCT01282177     History of Changes
Other Study ID Numbers: 114142
Study First Received: January 7, 2011
Last Updated: January 21, 2011
Health Authority: Canada: Ethics Review Committee

Keywords provided by Dalhousie University:
surveillance, safety , tolerability , vaccine

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
Respiratory Tract Diseases
Respiratory Tract Infections
RNA Virus Infections
Virus Diseases

ClinicalTrials.gov processed this record on October 30, 2014